Torrent Pharmaceuticals Limited — Montelukast Exporter Profile
Indian Pharmaceutical Exporter · #11 for Montelukast · $8.5M export value · DGFT Verified
Torrent Pharmaceuticals Limited is the #11 Indian exporter of Montelukast with $8.5M in export value and 77 verified shipments. Torrent Pharmaceuticals Limited holds a 3.2% market share in Montelukast exports across 13 countries. The company exports 43 pharmaceutical products worth $219.4M across 18 therapeutic categories.
Torrent Pharmaceuticals Limited — Montelukast Export Profile: Buyers & Destinations

Where Does Torrent Pharmaceuticals Limited Export Montelukast?
| Country | Value | Shipments | Share |
|---|---|---|---|
| SOUTH AFRICA | $2.1M | 57 | 30.6% |
| FINLAND | $1.2M | 52 | 17.7% |
| UNITED STATES | $568.8K | 16 | 8.4% |
| MALAYSIA | $473.2K | 22 | 7.0% |
| GERMANY | $433.5K | 24 | 6.4% |
| UNITED STATES OF AMERICA | $423.4K | 10 | 6.3% |
| UNITED KINGDOM | $405.2K | 29 | 6.0% |
| OMAN | $398.8K | 11 | 5.9% |
| UNITED ARAB EMIRATES | $354.3K | 18 | 5.3% |
| MALTA | $255.8K | 23 | 3.8% |
Torrent Pharmaceuticals Limited exports Montelukast to 15 countries. The largest destination is SOUTH AFRICA accounting for 30.6% of Torrent Pharmaceuticals Limited's Montelukast shipments, followed by FINLAND (17.7%) and UNITED STATES (8.4%). These destinations reflect Torrent Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Montelukast from Torrent Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ORION CORPORATION | FINLAND | $945.3K | 45 |
| TRINITY PHARMA (PTY) LTD | SOUTH AFRICA | $561.1K | 17 |
| DKSH MALAYSIA SDN BHD | MALAYSIA | $473.2K | 22 |
| HEUMANN PHARMA GMBH CO. GENERICA KG | MALTA | $437.3K | 26 |
| AL FARABI PHARMACY | OMAN | $398.8K | 11 |
| XXRREXX PHXXMA XXC XXMPOXXER XXIN XX6 4XX741XX | UNITED STATES OF AMERICA | $316.6K | 7 |
| TORRENT PHARMA INC | UNITED STATES | $311.2K | 10 |
| TRINITY PHARMA PTY LIMITED | SOUTH AFRICA | $279.7K | 9 |
| PHARMA DYNAMICS (PTY) LTD., | SOUTH AFRICA | $250.0K | 5 |
| TORRENT PHARMA (UK) LIMITED | UNITED KINGDOM | $232.2K | 16 |
Torrent Pharmaceuticals Limited supplies Montelukast to 53 buyers globally. The largest buyer is ORION CORPORATION (FINLAND), followed by TRINITY PHARMA (PTY) LTD (SOUTH AFRICA) and DKSH MALAYSIA SDN BHD (MALAYSIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Montelukast Export Value and How Much Does Torrent Pharmaceuticals Limited Contribute?
India exported $73.6M worth of Montelukast through 6,431 shipments from 510 suppliers to 138 countries, serving 1,324 buyers globally. Torrent Pharmaceuticals Limited contributes $8.5M to this total, accounting for 3.2% of India's Montelukast exports. Torrent Pharmaceuticals Limited ships Montelukast to 15 countries through 53 buyers.
What Is the Average Shipment Value for Torrent Pharmaceuticals Limited's Montelukast Exports?
Torrent Pharmaceuticals Limited's average Montelukast shipment value is $110.2K per consignment, based on 77 shipments totaling $8.5M. The largest destination is SOUTH AFRICA (30.6% of Torrent Pharmaceuticals Limited's Montelukast exports).
How Does Torrent Pharmaceuticals Limited Compare to Other Indian Montelukast Exporters?
Torrent Pharmaceuticals Limited ranks #11 among 510 Indian Montelukast exporters with a 3.2% market share. The top 3 exporters are UNICHEM LABORATORIES LIMITED ($13.1M), MACLEODS PHARMACEUTICALS LTD ($11.6M), DR.REDDY'S LABORATORIES LTD ($9.4M). Torrent Pharmaceuticals Limited processed 77 shipments to 13 destination countries.
What Montelukast Formulations Does Torrent Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| SINTAIR 10MG TABLET (MONTELUKAST 10MG) (NOS=3X10 TABLETS) | $300.0K | 6 |
| MONTELUKAST SODIUM CHEWABLE TABLETS 4MG | $200.0K | 4 |
| MONTELUKAST SODIUM CHEWABLE TABLETS | $199.5K | 5 |
| MONTEFLO 10 TABLET (MONTELUKAST SODIUM 1 | $183.9K | 4 |
| MONTELUKAST ORION 10 MG TABLET (MATERIAL | $183.0K | 7 |
| SINTAIR 10MG TABLET (MONTELUKAST 10MG) ( | $150.0K | 3 |
| MONTELUKAST SODIUM 10MG TABLETS USP | $150.0K | 3 |
| OTHER-MONTEFLO 10 TABLET (MONTELUKAST SODIUM 10 MG) NOS SIZE 3 X 10 TABLETS | $144.6K | 3 |
| MONTEFLO 10 TABLET (MONTELUKAST SODIUM 10MG)(NOS=3X10 TAB) | $102.3K | 3 |
| OTHER - MONTELUKAST HEUMANN 10 MG TABLET | $102.2K | 8 |
Torrent Pharmaceuticals Limited exports 188 distinct Montelukast formulations including tablets, capsules, syrups, and combination drugs. The top formulation is SINTAIR 10MG TABLET (MONTELUKAST 10MG) (NOS=3X10 TABLETS) with 6 shipments worth $300.0K.
Regulatory Requirements: Exporting Montelukast to Key Markets
What Torrent Pharmaceuticals Limited must comply with to export Montelukast to its top destination countries
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Torrent Pharmaceuticals Limited Compare to Nearest Montelukast Exporters?
Exporters ranked immediately above and below #11 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 8 | INTAS PHARMACEUTICALS LIMITED | $3.8M | 400 | 10 | $9.4K |
| 10 | MSN LABORATORIES PRIVATE LIMITED | $3.2M | 295 | 18 | $10.7K |
| 11 | TORRENT PHARMACEUTICALS LIMITED ★ | $3.1M | 77 | 13 | $39.7K |
| 9 | INDOCO REMEDIES LIMITED | $3.0M | 61 | 2 | $50.0K |
| 7 | HETERO LABS LIMITED | $2.9M | 58 | 8 | $50.0K |
Torrent Pharmaceuticals Limited ranks #11 among 510 Indian Montelukast exporters. Average shipment value of $39.7K compared to the market average of $144.3K. The closest competitors by value are INTAS PHARMACEUTICALS LIMITED and MSN LABORATORIES PRIVATE LIMITED.
Which Indian Ports Ship Montelukast Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 537 | 8.4% |
| NHAVA SHEVA SEA (INNSA1) | 528 | 8.2% |
| SAHAR AIR | 479 | 7.4% |
| SAHAR AIR CARGO ACC (INBOM4) | 466 | 7.2% |
| DELHI AIR | 451 | 7.0% |
| JNPT/ NHAVA SHEVA SEA | 286 | 4.4% |
| JNPT | 224 | 3.5% |
| MUNDRA SEA | 214 | 3.3% |
Geopolitical & Trade Policy Impact on Torrent Pharmaceuticals Limited's Montelukast Exports
The global pharmaceutical export landscape is currently navigating a series of geopolitical challenges that have direct implications for Indian exporters like Torrent Pharmaceuticals.
The ongoing Israel-Iran tensions have led to disruptions in the Red Sea shipping routes, a critical corridor for Indian pharmaceutical exports to the Middle East and North Africa (MENA) region. Maritime carriers have suspended bookings and rerouted shipments via the Cape of Good Hope, resulting in longer transit times and increased shipping costs. These disruptions are particularly concerning for time-sensitive pharmaceutical products, as extended lead times can affect product efficacy and shelf life. (pharmaceuticalcommerce.com)
In the United States, recent tariff policies have introduced additional complexities. The U.S. administration's imposition of broad tariffs on imports from over 60 countries, including India, has raised concerns about the competitiveness of Indian pharmaceutical products in the U.S. market. While health products have been exempted from these tariffs, the potential for future policy changes necessitates vigilance. (apnews.com)
The European Union's regulatory landscape is also evolving, with stringent compliance requirements under the Falsified Medicines Directive (FMD). Indian exporters must ensure adherence to these regulations to maintain market access. Non-compliance could result in significant market share losses in the EU, a key export destination for Torrent Pharmaceuticals.
Torrent Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Quality compliance remains a critical focus for Indian pharmaceutical exporters. The U.S. Food and Drug Administration (FDA) has intensified inspections of Indian manufacturing facilities, conducting over 200 inspections in 2023, with plans to increase this number in 2024. This heightened scrutiny underscores the importance of adhering to Good Manufacturing Practices (GMP) to ensure product quality and maintain export eligibility. (fact.net.in)
Torrent Pharmaceuticals has proactively addressed these regulatory challenges by investing in quality control systems and infrastructure. The company's commitment to compliance is evident in its consistent financial performance and sustained market presence. However, the broader Indian pharmaceutical sector continues to grapple with issues related to counterfeit drugs and quality concerns, which can impact the reputation of even compliant companies.
About Torrent Pharmaceuticals Limited
Torrent Pharmaceuticals Limited exports 43 products worth $219.4M. Beyond Montelukast, top products include Pantoprazole, Citalopram, Rosuvastatin, Escitalopram, Sertraline. View the complete Torrent Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Montelukast — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Montelukast shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Torrent Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 298 individual customs records matching Torrent Pharmaceuticals Limited exporting Montelukast, covering 188 formulations to 15 countries via 53 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 138+ countries, 1,324+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Montelukast Export Data from Torrent Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Torrent Pharmaceuticals Limited's Montelukast exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Torrent Pharmaceuticals Limited
Full Company Profile →
43 products · $219.4M total trade · 18 categories
Montelukast Stats
Company Overview
Top Products by Torrent Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Torrent Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Montelukast. For current shipment-level data, contact TransData Nexus.